Want to see CTXR full AI Analyst Report?
Top Page
Citius Pharmaceuticals
(NASDAQ:CTXR)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.41
▼(-31.83% Downside)
Action:Reiterated
Date:10/21/26
The score is held down primarily by heavy operating losses and persistent cash burn, which imply continued financing risk despite improving TTM revenue. Technicals also remain weak with a clear downtrend and negative momentum. Offsetting factors include low leverage on the balance sheet and a positive commercial-launch update for LYMPHIR, though Nasdaq bid-price compliance risk remains a notable overhang.
Positive Factors
LYMPHIR Commercial Momentum
LYMPHIR is showing measurable early commercial traction, with broader institutional adoption, rising vial orders, and near-universal payer coverage. These developments can improve patient access, support recurring demand, and establish a stronger commercial base for expansion in the underserved CTCL market.
Negative Factors
Large Operating Losses
The scale of operating and net losses remains far larger than current revenue and gross profit, showing that the cost structure is still well ahead of commercialization. Persistent losses can erode the capital base and make achieving sustainable profitability dependent on substantial future product progress.
Read all positive and negative factors
Positive Factors
Negative Factors
LYMPHIR Commercial Momentum
LYMPHIR is showing measurable early commercial traction, with broader institutional adoption, rising vial orders, and near-universal payer coverage. These developments can improve patient access, support recurring demand, and establish a stronger commercial base for expansion in the underserved CTCL market.
Read all positive factors
Citius Pharmaceuticals (CTXR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.07M
Dividend YieldN/A
Average Volume (3M)206.28K
Price to Earnings (P/E)―
Beta (1Y)2.97
Revenue GrowthN/A
EPS Growth57.48%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.11
Shares Outstanding27,452,570
10 Day Avg. Volume258,323
30 Day Avg. Volume206,277
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.52
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue2.15
Enterprise Value/Gross Profit10.77
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
$4.00Price Target Upside566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.81
Revenue Forecast (FY)$52.58M
Citius Pharmaceuticals Business Overview & Revenue Model
Company Description
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cance...
Citius Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Dec 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.42M | -214.25K | -209.61K | 0.00 | 0.00 | -164.87K |
| EBITDA | -57.19M | -38.20M | -38.64M | -36.54M | -33.14M | -23.37M |
| Net Income | -46.27M | -37.43M | -39.14M | -32.54M | -33.64M | -23.05M |
Balance Sheet | ||||||
| Total Assets | 142.26M | 130.94M | 116.65M | 103.61M | 114.00M | 142.43M |
| Cash, Cash Equivalents and Short-Term Investments | 17.01M | 4.25M | 3.25M | 26.48M | 41.71M | 70.07M |
| Total Debt | 7.18M | 1.81M | 262.87K | 481.25K | 678.23K | 855.47K |
| Total Liabilities | 66.35M | 53.41M | 42.55M | 12.18M | 10.57M | 9.65M |
| Stockholders Equity | 66.61M | 67.55M | 70.08M | 90.83M | 102.83M | 132.18M |
Cash Flow | ||||||
| Free Cash Flow | -34.87M | -26.55M | -28.20M | -29.06M | -28.36M | -64.26M |
| Operating Cash Flow | -34.87M | -26.55M | -28.20M | -29.06M | -28.36M | -24.25M |
| Investing Cash Flow | -12.75M | -5.75M | -5.00M | 0.00 | 0.00 | -40.01M |
| Financing Cash Flow | 58.54M | 33.30M | 9.97M | 13.83M | 0.00 | 120.47M |
Citius Pharmaceuticals Technical Analysis
Negative
0.60
Price Trends
0.55
Negative
0.56
Negative
0.67
Negative
Market Momentum
-0.04
Positive
30.97
Neutral
10.18
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTXR, the sentiment is Negative. The current price of 0.6 is above the 20-day moving average (MA) of 0.48, above the 50-day MA of 0.55, and below the 200-day MA of 0.67, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 30.97 is Neutral, neither overbought nor oversold. The STOCH value of 10.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTXR.
Citius Pharmaceuticals Risk Analysis
Citius Pharmaceuticals disclosed 59 risk factors in its most recent earnings report. Citius Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Citius Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $11.07M | -0.19 | -67.15% | ― | ― | 57.48% | |
46 Neutral | $11.87M | -0.77 | -64.75% | ― | -62.70% | -121.27% | |
45 Neutral | $10.58M | -1.14 | -47.22% | ― | -91.94% | 55.29% | |
44 Neutral | $12.70M | -0.82 | -748.08% | ― | ― | ― | |
41 Neutral | $9.10M | -0.97 | -115.00% | ― | ― | ― | |
39 Underperform | $3.68M | >-0.01 | -222.32% | ― | ― | 78.25% |
* Healthcare Sector Average
CTXR
Citius Pharmaceuticals
0.40
-1.21
-75.05%
BLRX
Bioline RX Ltd Sponsored ADR
2.04
-1.72
-45.74%
PTN
Palatin Technologies
5.11
-0.64
-11.13%
DARE
Daré Bioscience
0.65
-1.38
-68.23%
LPCN
Lipocine
1.44
-1.38
-48.94%
KALA
KALA BIO
0.19
-40.10
-99.53%
Citius Pharmaceuticals Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Citius Pharmaceuticals Receives Nasdaq Extension to Regain Compliance
Negative
Aug 21, 2026
On August 17, 2026, Citius Pharmaceuticals disclosed that Nasdaq granted the company an extension until February 8, 2027, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The com...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Citius Oncology reports strong LYMPHIR U.S. launch momentum
Positive
Aug 5, 2026
On August 5, 2026, Citius Oncology reported strong commercial momentum for LYMPHIR’s U.S. launch, highlighting rapid uptake among treatment centers and wholesalers. The number of new institutions ordering LYMPHIR rose 78% quarter over quarte...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.